IN8bio
INAB
14 hedge funds and large institutions have $7.02M invested in IN8bio in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 0 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
8% more funds holding
Funds holding: 13 → 14 (+1)
0.05% more ownership
Funds ownership: 0.32% → 0.36% (+0.05%)
10% less capital invested
Capital invested by funds: $7.8M → $7.02M (-$784K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$586K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$258K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$224K |
| 4 |
BlackRock
New York
|
+$25.2K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$15.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$76.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$32.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Capital World Investors
Los Angeles,
California
| $2.78M | – | – | – |
|
|
NCM
2
Nantahala Capital Management
New Canaan,
Connecticut
| $1.23M | -$76.2K | -681 | -5% |
|
|
VC
3
Voss Capital
Houston,
Texas
| $875K | +$586K | +5,240 | +154% |
|
|
BRF
4
B. Riley Financial
Los Angeles,
California
| $858K | +$559 | +5 | +0.1% |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $372K | -$32.6K | -291 | -7% |
|
|
SPC
6
Sigma Planning Corp
Ann Arbor,
Michigan
| $326K | +$258K | +2,305 | +242% |
|
7
Ensign Peak Advisors
Salt Lake City,
Utah
| $243K | – | – | – |
|
|
BCM
8
Bridgeway Capital Management
Houston,
Texas
| $208K | +$224K | +2,000 | New |
|
|
9
BlackRock
New York
| $54K | +$25.2K | +225 | +71% |
|
|
10
HighTower Advisors
Chicago,
Illinois
| $47K | +$15.6K | +139 | +42% |
|
11
UBS Group
Zurich,
Switzerland
| $13K | +$7.83K | +70 | +121% |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $11K | +$783 | +7 | +7% |
|
13
Morgan Stanley
New York
| $10K | +$3.69K | +33 | +52% |
|
INAB Hedge Fund Activity: Q1 2022 in Review
14 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q1 2022, worth a combined $7.02M — down 10% from $7.8M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new INAB positions and 0 closed out — a net gain of 1 holder — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Voss Capital, adding an estimated $586K. The largest seller was Nantahala Capital Management, cutting an estimated $76.2K.
- 14 institutional investors held IN8bio (INAB) as of Q1 2022, up from 13 in Q4 2021.
- Funds reported $7.02M of IN8bio stock for Q1 2022, down 10% quarter-over-quarter.
- 1 fund opened new IN8bio positions in Q1 2022 and 0 closed out, a net change of +1 holder.
- The largest IN8bio buyer in Q1 2022 was Voss Capital, an estimated $586K added.
- The largest IN8bio seller in Q1 2022 was Nantahala Capital Management, an estimated $76.2K sold.
Based on aggregated 13F filings for Q1 2022.